Robert E. Landry - 17 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
17 Jan 2024
Net transactions value
-$140,558
Form type
4
Filing time
18 Jan 2024, 16:02:18 UTC
Previous filing
17 Jan 2024
Next filing
25 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $189,490 +500 +2.2% $378.98 23,338 17 Jan 2024 Direct
transaction REGN Common Stock Tax liability $330,048 -354 -1.5% $932.34 22,984 17 Jan 2024 Direct
holding REGN Common Stock 270 17 Jan 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -500 -3.4% $0.000000 14,187 17 Jan 2024 Common Stock 500 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.